These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37735009)

  • 1. Effects of elexacaftor/tezacaftor/ivacaftor on liver fibrosis markers in adults with cystic fibrosis.
    Tewkesbury DH; Scott J; Barry PJ; Bright-Thomas RJ; Hanley KP; Athwal V; Jones AM
    J Cyst Fibros; 2024 Mar; 23(2):349-353. PubMed ID: 37735009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunosuppressant management upon elexacaftor/tezacaftor/ivacaftor initiation in cystic fibrosis patients with prior liver transplant.
    Coman D; Vincent C; Huard G; Marleau D; Lavoie A; Hercun J
    J Cyst Fibros; 2024 May; 23(3):561-562. PubMed ID: 38000917
    [No Abstract]   [Full Text] [Related]  

  • 3. Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey.
    Çobanoğlu N; Özçelik U; Çakır E; Şişmanlar Eyüboğlu T; Pekcan S; Cinel G; Yalçın E; Kiper N; Emiralioğlu N; Şen V; Şen HS; Ercan Ö; Çokuğraş H; Kılınç AA; Al Shadfan LM; Yazan H; Altıntaş DU; Karagöz D; Demir E; Kartal Öztürk G; Bingöl A; Başaran AE; Sapan N; Çekiç Ş; Çelebioğlu E; Aslan AT; Gürsoy TR; Tuğcu G; Özdemir A; Harmancı K; Yıldırım GK; Köse M; Hangül M; Tamay Z; Süleyman A; Yüksel H; Yılmaz Ö; Özcan G; Topal E; Can D; Korkmaz Ekren P; Çaltepe G; Kılıç M; Özdoğan Ş; Doğru D
    Pediatr Pulmonol; 2020 Sep; 55(9):2302-2306. PubMed ID: 32453906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical effectiveness of elexacaftor/tezacaftor/ivacaftor in a man with A559T and 3120+1G>CFTR variants.
    Mitchell E; Albon D
    Pediatr Pulmonol; 2024 Jul; 59(7):2009-2011. PubMed ID: 38607232
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy of Elexacaftor-Tezacaftor-Ivacaftor on chronic rhinosinusitis in cystic fibrosis.
    Di Gioia S; Lucca F; Venditto L; Sandri G; Tommasi N; Cipolli M; Molteni G
    Am J Otolaryngol; 2024; 45(3):104236. PubMed ID: 38417261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elexacaftor/Tezacaftor/Ivacaftor therapy in cystic fibrosis children previously CFSPID: Is it over-medicalization?
    Terlizzi V
    J Cyst Fibros; 2024 Mar; 23(2):366-367. PubMed ID: 37838487
    [No Abstract]   [Full Text] [Related]  

  • 7. Triple Therapy for Cystic Fibrosis
    Barry PJ; Mall MA; Álvarez A; Colombo C; de Winter-de Groot KM; Fajac I; McBennett KA; McKone EF; Ramsey BW; Sutharsan S; Taylor-Cousar JL; Tullis E; Ahluwalia N; Jun LS; Moskowitz SM; Prieto-Centurion V; Tian S; Waltz D; Xuan F; Zhang Y; Rowe SM; Polineni D;
    N Engl J Med; 2021 Aug; 385(9):815-825. PubMed ID: 34437784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations in the fecal microbiota in patients with advanced cystic fibrosis liver disease after 6 months of elexacaftor/tezacaftor/ivacaftor.
    Duong JT; Pope CE; Hayden HS; Miller C; Salipante SJ; Rowe SM; Solomon GM; Nichols D; Hoffman LR; Narkewicz MR; Green N
    J Cyst Fibros; 2024 May; 23(3):490-498. PubMed ID: 38448281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
    Southern KW; Murphy J; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Keating D; Marigowda G; Burr L; Daines C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Sass LA; Tullis E; McKee CM; Moskowitz SM; Robertson S; Savage J; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Taylor-Cousar JL;
    N Engl J Med; 2018 Oct; 379(17):1612-1620. PubMed ID: 30334692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medication utilization and lung function changes after initiation of treatment with elexacaftor/tezacaftor/ivacaftor.
    De Vuyst R; Kam CW; McKinzie CJ; Esther CR
    Pediatr Pulmonol; 2024 Jul; 59(7):2051-2054. PubMed ID: 38629427
    [No Abstract]   [Full Text] [Related]  

  • 12. Ivacaftor-elexacaftor-tezacaftor and tacrolimus combination in cystic fibrosis.
    Smith M; Ryan KJ; Gutierrez H; Sanchez LHG; Anderson JN; Acosta EP; Benner KW; Guimbellot JS
    J Cyst Fibros; 2022 Jan; 21(1):e8-e10. PubMed ID: 34130909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease with the Phe508del/minimal function genotype.
    Carnovale V; Iacotucci P; Terlizzi V; Colangelo C; Medio P; Ferrillo L; De Gregorio F; Francalanci M; Taccetti G; Buonaurio S; d'Ippolito M; Marsicovetere G; D'Andria M; Ferrara N; Salvatore D
    Respir Med; 2021; 189():106646. PubMed ID: 34673344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral lung effect of elexacaftor/tezacaftor/ivacaftor in adult cystic fibrosis.
    Stylemans D; Darquenne C; Schuermans D; Verbanck S; Vanderhelst E
    J Cyst Fibros; 2022 Jan; 21(1):160-163. PubMed ID: 33832855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM;
    N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
    Sutharsan S; McKone EF; Downey DG; Duckers J; MacGregor G; Tullis E; Van Braeckel E; Wainwright CE; Watson D; Ahluwalia N; Bruinsma BG; Harris C; Lam AP; Lou Y; Moskowitz SM; Tian S; Yuan J; Waltz D; Mall MA;
    Lancet Respir Med; 2022 Mar; 10(3):267-277. PubMed ID: 34942085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term effect of elexacaftor-tezacaftor-ivacaftor on lung function and transplant planning in cystic fibrosis patients with advanced lung disease.
    B B; A R; G R; A N; D G; S G; P F; M SG; L C; B G
    J Cyst Fibros; 2021 Sep; 20(5):768-771. PubMed ID: 34162524
    [No Abstract]   [Full Text] [Related]  

  • 18. Lung clearance index (LCI
    Urquhart DS; Dowle H; Moffat K; Forster J; Cunningham S; Macleod KA
    Pediatr Pulmonol; 2024 May; 59(5):1449-1453. PubMed ID: 38415920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic Enhancement of Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis: A Cost Reduction Strategy to Address Global Disparities in Access.
    Hong E; Zampoli M; Beringer PM
    Clin Pharmacol Ther; 2024 Jun; 115(6):1204-1207. PubMed ID: 38385853
    [No Abstract]   [Full Text] [Related]  

  • 20. Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor Therapy in Three Subjects with the Cystic Fibrosis Genotype Phe508del/Unknown and Advanced Lung Disease.
    Terlizzi V; Colangelo C; Marsicovetere G; D'Andria M; Francalanci M; Innocenti D; Masi E; Avarello A; Taccetti G; Amato F; Comegna M; Castaldo G; Salvatore D
    Genes (Basel); 2021 Jul; 12(8):. PubMed ID: 34440351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.